I was recently watching a series called The Last Samurai Standing, which takes place in Japan during the Meiji Restoration. One of the story’s unique healthcare plots was a Cholera epidemic ravaging Japan at the time. It is believed that more than 100,000 people died during the two outbreaks during that time, forcing the country to set up a policy on infectious disease control. But today, Japan has hardly any Cholera cases, with only 100 reported from 1998 to 2008. But the disease vector has changed, with Japan seeing more than a million Cancer cases annually. Its the leading cause of death in Japan. India is no different; we had 58 deaths due to Cholera last year, but Cancer is definitely a healthcare issue in the country. On World Cancer Day, let’s look at how India is closing the Cancer Gap.

Let’s start at the national level, because cancer in India is no longer a marginal health issue—it’s a system-defining one.

India currently sees ~1.4–1.5 million new cancer cases every year, and projections suggest this could cross 2 million annually by 2040. Nearly 60% of patients are still diagnosed at Stage III or IV, which remains the single biggest driver of poor outcomes. That said, the last decade has quietly reshaped India’s ability to respond.

One of the most meaningful shifts has been financial risk protection. Under Ayushman Bharat, oncology has emerged as one of the highest-utilisation categories. Chemotherapy, radiotherapy, surgery, and select diagnostic tests are now reimbursed across thousands of empanelled hospitals. This hasn’t eliminated out-of-pocket spending—but it has slowed the financial freefall that cancer often triggered earlier.

Infrastructure has also expanded—and crucially, decentralised. India now has 600+ radiotherapy units, nearly double what it had a decade ago. Chemotherapy day-care units, nuclear medicine facilities, and oncology services are increasingly present in Tier 2 and Tier 3 cities. While gaps remain, access is no longer as metro-locked as it once was.

Screening has finally entered the public-health mainstream. Population-based screening for oral, breast, and cervical cancers—three of India’s highest-burden cancers—has been embedded into Health & Wellness Centres. Oral cancer screening, in particular, has shown real-world impact in high tobacco-use states. This is slow, unglamorous work—but it’s foundational.

Two institutions deserve special attention—not as symbols, but as system builders.

The National Cancer Grid has connected 300+ cancer centres across the country. Its real contribution isn’t infrastructure—it’s standardisation. Common treatment guidelines, uniform protocols, shared training, and collaborative research have reduced unwarranted variation in care. In a country as diverse as India, consistency itself is a form of innovation.

At the centre of this ecosystem sits Tata Memorial Hospital. Beyond being one of Asia’s largest cancer centres, it also influences workforce training, clinical trials, guideline development, and policy advisory services. A large proportion of India’s oncology talent has been trained, directly or indirectly, through Tata Memorial—making it the system’s anchor institution.

Add to this India’s rise as a global supplier of oncology generics and biosimilars, and the affordability equation has fundamentally changed. Treatments that once cost lakhs per cycle are now available at a fraction of the price—often making the difference between continuing and abandoning care.

Finally, cancer data systems have matured. Registry coverage has expanded, improving visibility into incidence patterns, geographic hotspots, and trends. While still incomplete, this data now informs screening priorities and infrastructure planning—something that simply wasn’t possible at scale ten years ago.

State-Level Reality: Leaders and Laggards

Zooming in, it becomes clear that cancer outcomes in India are decided at the state level.

States setting the benchmark

• Kerala reports higher cancer incidence, largely because of better detection and reporting. Strong primary care, higher screening uptake (especially for breast and cervical cancer), and earlier-stage diagnosis translate into better outcomes. This is what system maturity looks like.
• Tamil Nadu stands out for decentralised oncology infrastructure and strong public-sector integration. Alignment with National Cancer Grid protocols, state insurance coverage, and multiple functional cancer centres reduces dependence on metros and improves treatment continuity.
• Maharashtra combines scale with capability. Anchored by Tata Memorial, the state has benefitted from workforce depth, research capacity, and protocol-led oncology care. Urban–rural disparities persist, but Maharashtra remains one of India’s strongest oncology ecosystems.

States that need accelerated focus

• Bihar continues to struggle with low screening coverage and late-stage presentation. Most advanced care still requires out-of-state travel, increasing delays and financial toxicity. The gap here is less about technology and more about primary care integration and referral pathways.
• Uttar Pradesh, despite its population size, remains underserved relative to need. Oncology infrastructure per capita is low, registry coverage is improving but incomplete, and late diagnosis is common. Even modest gains here would have an outsized national impact.
• North-Eastern states report some of the highest cancer incidence rates, particularly tobacco-related cancers, yet face persistent access barriers due to geography, workforce shortages, and fragmented referral systems.

This variation clearly shows that cancer outcomes are driven less by medical breakthroughs and more by state-level system design choices.

From Foundations to Outcomes

India has spent the last decade building the rails of cancer care—financing mechanisms, infrastructure, standardised protocols, networks such as the National Cancer Grid, and anchor institutions such as Tata Memorial Hospital. That work matters.

But the next decade will be judged on outcomes, not effort.

Fewer late-stage diagnoses.
Lower financial toxicity.
More consistent survival across states—not just in centres of excellence.

World Cancer Day is not about declaring victory. It’s about recognising that cancer is now a test of execution. India has laid the foundations. The real question is whether it can convert them—state by state—into earlier detection, affordable care, and better lives for patients.